Development of a 2,4-diaminothiazole series for the treatment of human African trypanosomiasis highlights the importance of static-cidal screening of analogues

Laura A. T. Cleghorn, Richard J. Wall, Sébastien Albrecht, Stuart A. MacGowan, Suzanne Norval, Manu De Rycker, Andrew Woodland, Daniel Spinks, Stephen Thompson, Stephen Patterson, Victoriano Corpas Lopez, Gourav Dey, Iain T. Collie, Irene Hallyburton, Robert Kime, Frederick R. C. Simeons, Laste Stojanovski, Julie A. Frearson, Paul G. Wyatt, Kevin D. ReadIan H. Gilbert (Lead / Corresponding author), Susan Wyllie (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

39 Downloads (Pure)

Abstract

While treatment options for human African trypanosomiasis (HAT) have improved significantly, there is still a need for new drugs with eradication now a realistic possibility. Here, we report the development of 2,4-diaminothiazoles that demonstrate significant potency against Trypanosoma brucei, the causative agent of HAT. Using phenotypic screening to guide structure-activity relationships, potent drug-like inhibitors were developed. Proof of concept was established in an animal model of the hemolymphatic stage of HAT. To treat the meningoencephalitic stage of infection, compounds were optimized for pharmacokinetic properties, including blood-brain barrier penetration. However, in vivo efficacy was not achieved, in part due to compounds evolving from a cytocidal to a cytostatic mechanism of action. Subsequent studies identified a nonessential kinase involved in the inositol biosynthesis pathway as the molecular target of these cytostatic compounds. These studies highlight the need for cytocidal drugs for the treatment of HAT and the importance of static-cidal screening of analogues.

Original languageEnglish
Pages (from-to)8896–8916
Number of pages21
JournalJournal of Medicinal Chemistry
Volume66
Issue number13
Early online date21 Jun 2023
DOIs
Publication statusPublished - 13 Jul 2023

Fingerprint

Dive into the research topics of 'Development of a 2,4-diaminothiazole series for the treatment of human African trypanosomiasis highlights the importance of static-cidal screening of analogues'. Together they form a unique fingerprint.

Cite this